A surveillance method for the early identification of idiosyncratic adverse drug reactions

Drug Safety

Volumn 31, Issue 2, 2008, Pages 169-180

  Etwel, Fatma A ^a   Rieder, Michael J ^a   Bend, John R ^a   Koren, Gideon ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Adverse drug reactions; Adverse reaction monitoring; Liver injury, drug induced; Pemoline, adverse reactions; Pharmacovigilance

Indexed keywords

PEMOLINE; PEMOLINE MAGNESIUM;

ADVERSE OUTCOME; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; FISHER EXACT TEST; FOOD AND DRUG ADMINISTRATION; HUMAN; IDIOPATHIC DISEASE; INCIDENCE; LIVER FAILURE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; PRIORITY JOURNAL; PROBABILITY; RISK FACTOR; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 38549157094     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831020-00006     Document Type: Article

References (36)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279 (15): 1200-5
2. Stricker BC, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004; 329 (7456): 44-7
3. Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Fortnightly review: adverse drug reactions. BMJ 1998; 316 (7140): 1295-8
4. Meyboom RH, Egberts AC, Edwards IR, et al. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16 (6): 355-65
5. Begaud B, Moride Y, Tubert-Bitter P, et al. False-positives in spontaneous reporting: should we worry about them? Br J Clin Pharmacol 1994; 38 (5): 401-4
6. Lortie FM. Postmarketing surveillance of adverse drug reactions: problems and solutions. CMAJ 1986; 135: 27-32
7. Zielinski SL. FDA attempting to overcome major roadblocks in monitoring drug safety. J Natl Cancer Inst 2005; 97 (12): 872-3
8. Millichap JG. The hyperactive child. Practitioner 1976; 217 (1297): 61-5
9. Stevenson RD, Wolraich ML. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Pediatr Clin North Am 1989; 36 (5): 1183-97
10. Berkovitch M, Pope E, Phillips J, et al. Pemoline-associated fulminant liver failure: testing the evidence for causation. Clin Pharmacol Ther 1995; 57 (6): 696-8
11. Jaffe SL. Pemoline and liver function. J Am Acad Child Adolesc Psychiatry 1989; 28 (3): 457-8
12. Nehra A, Mullick F, Ishak KG, et al. Pemoline-associated hepatic injury. Gastroenterology 1990; 99 (5): 1517-9
13. Willy ME, Manda B, Shatin D, et al. A study of compliance with FDA recommendations for pemoline (cylert). J Am Acad Child Adolesc Psychiatry 2002; 41 (7): 785-90
14. Hogan V. Pemoline (cylert): market withdrawal. Can Med Assoc J 2000; 162 (1): 106, 110
15. Pemoline removed from US market. Formulary 2005; 40 (11): 373
16. Naranjo CA, Busto U, Sellers EM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (2): 239-45
17. Liu E, Dobyns E, Narkewicz M, et al. Acute hepatic failure in children: a seven year experience at a children's hospital [abstract]. Hepatology 2001; 34: 197A
18. Children Defence Fund [online]. Available from URL: http://www. childrensdefense.org/site/DocServer/us-2.pdf?docID=-958 [Accessed 2008 Jan 4]
19. Devictor D, Desplanques L, Debray D, et al. Emergency liver transplantation for fulminant liver failure in infants and children. Hepatology 1992; 16 (5): 1156-62
20. Devictor D, Tahiri C, Rousset A, et al. Management of fulminant hepatic failure in children: an analysis of 56 cases. Crit Care Med 1993; 21 (9 Suppl.): S348-9
21. Liu E, MacKenzie T, Dobyns EL, et al. Characterization of acute liver failure and development of a continuous risk of death staging system in children. J Hepatol 2006; 44 (1): 134-41
22. Krager JM, Safer D, Earhart J. Follow-up survey results of medication used to treat hyperactive school children. J Sch Health 1979; 49 (6): 317-21
23. Safer DJ, Krager JM. Trends in medication treatment of hyperactive school children: results of six biannual surveys. Clin Pediatr 1983; 22 (7): 500-4
24. Safer DJ, Krager JM. Prevalence of medication treatment for hyperactive adolescents. Psychopharmacol Bull 1985; 21 (2): 212-5
25. Safer DJ, Krager JM. A survey of medication treatment for hyperactive/inattentive students. JAMA 1988; 260 (15): 2256-8
26. Safer DJ, Krager JM. The increased rate of stimulant treatment for hyperactive/inattentive students in secondary schools. Pediatrics 1994; 94 (4 Pt 1): 462-4
27. Mitchell BR. International historical statistics: the Americas, 1750-2000. 5th ed. New York: Palgrave Macmillan, 2003
28. Canadian drug identification code book. 8th ed. Ottawa (ON): Health and Welfare Canada, 1981
29. Canadian Pharmaceutical Association, Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. Toronto (ON): Canadian Pharmaceutical Association, 1986
30. Pratt DS, Dubois RS. Hepatotoxicity due to pemoline (cylert): a report of two cases. J Pediatr Gastroenterol Nutr 1990; 10 (2): 239-41
31. Adcock KG, MacElroy DE, Wolford ET, et al. Pemoline therapy resulting in liver transplantation. Ann Pharmacother 1998; 32 (4): 422-5
32. Hochman JA, Woodard SA, Cohen MB. Exacerbation of autoimmune hepatitis: another hepatotoxic effect of pemoline therapy. Pediatrics 1998; 101 (1 Pt 1): 106-8
33. Marotta PJ, Roberts EA. Pemoline hepatotoxicity in children. J Pediatr 1998; 132 (5): 894-7
34. Rosh JR, Delert SF, Narkewicz M, et al. Four cases of severe hepatotoxicity associated with pemoline: possible autoimmune pathogenesis. Pediatrics 1998; 101 (5): 921-3
35. Capella D, Pedros C, Vidal X, et al. Case-population studies in pharmacoepidemiology. Drug Saf 2002; 25: 7-19
36. Safer DJ, Zito JM, Gardner JF. Pemoline hepatotoxicity and postmarketing surveillance. J Am Acad Child Adolesc Psychiatry 2001; 40 (6): 622-9